Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363517 | 0.85 | EGFR (0.42) | FGFR1LCK | |
| SCHEMBL13391215 | 0.84 | ADORA2A (0.44) | LCKJAK2JAK1JAK3 | |
| SCHEMBL2304205 | 0.80 | TAS1R3 (0.42) | — | |
| SCHEMBL2303397 | 0.79 | ADORA2A (0.49) | SMN1; SMN2 | |
| SCHEMBL2303842 | 0.79 | ADORA2A (0.49) | SMN1; SMN2 | |
| SCHEMBL2308055 | 0.79 | ADORA2A (0.49) | SMN1; SMN2 | |
| SCHEMBL2303704 | 0.78 | MAOB (0.43) | FGFR1P2RY12JAK2JAK1TYK2 | |
| SCHEMBL2301677 | 0.78 | ADORA2A (0.39) | FGFR1LCKLMNASMN1; SMN2NPC1 | |
| SCHEMBL2685086 | 0.78 | ADORA2A (0.39) | FGFR1LCKLMNASMN1; SMN2NPC1 | |
| SCHEMBL2301672 | 0.78 | ADORA2A (0.39) | FGFR1LCKLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350073-B1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2350073-A1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010034799-A1 | 3H-IMIDAZ0 [4, 5-B] PYRIDINE- 6 -CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | FGFR1 652/4885LCK 1097/4885P2RY12 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.